Cairo – Mubasher: Sabaa International Company for Pharmaceutical and Chemical Industry is expected to produce 250,000 doses of Favipiravir for the treatment of coronavirus (COVID-19) during six months starting from the date of production.
The pharmaceutical firm received an initial approval from the Egyptian Drug Authority (EDA) to register its drug product, according to a bourse disclosure on Wednesday.
The registration procedures are projected to be complete within three months.
The company expects the public price for every dose to between EGP 1,000 and EGP 1,200. The final price will be determined by the regulatory authorities.
It is worth mentioning that during the first quarter of 2020, the pharmaceutical company reported net profits of EGP 3.16 million, up from about EGP 724,830 in the year-ago period.
